A report on Gene Therapy for Age-related Macular Degeneration market compiled by Brand Essence Market Research provides a succinct analysis regarding the values and trends existing in the current business scenario. The study also offers a brief summary of market valuation, market size, regional outlook and profit estimations of the industry. Furthermore, the report examines the competitive sphere and growth strategies of leading players in the Gene Therapy for Age-related Macular Degeneration market.
In 2018, the GlobalGene Therapy for Age-related Macular Degeneration Marketsize was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
Download Premium Sample of the Report:https://industrystatsreport.com/Request/Sample?ResearchPostId=1&RequestType=Sample
Key playersof the Gene Therapy for Age-related Macular Degeneration market are RetroSense Therapeutics, REGENXBIO, AGTC
Gene Therapy for Age-related Macular Degeneration Market Segmentation:
Product Type: Subretinal,Intravitreal,Unspecified
Application: Monotherapy,Combination Therapy
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)
Table of Contents
1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered
2 Global Growth Trends2.1 Gene Therapy for Age-related Macular Degeneration Market Size2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2014-2025)2.2.2 Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities
3 Market Share by Key Players3.1 Gene Therapy for Age-related Macular Degeneration Market Size by Manufacturers3.1.1 Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019)3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)3.2 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served3.3 Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service3.4 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market3.5 Mergers & Acquisitions, Expansion Plans
About us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at[emailprotected]
See original here:
What is Trending in Gene Therapy for Age-related Macular Degeneration Market? What are the Strategies to Boost Business in Near Years? - Owned
- Unraveling The Complexity Of Cell Therapy: Advancements And Challenges - Life Science Leader Magazine - November 27th, 2024
- Novartis wagers more than $1B on gene therapies for the nervous system - BioPharma Dive - November 27th, 2024
- Gene therapy for geographic atrophy in age-related macular degeneration: current insights - Nature.com - November 27th, 2024
- Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT - November 27th, 2024
- At MGB's gene therapy institute, effort to win first venture capital investments continues - The Business Journals - November 27th, 2024
- Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy - Fierce Biotech - November 27th, 2024
- Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy - CGTLive - November 27th, 2024
- Why This Gene-Therapy Companys Stock Is Rising 228% - Yahoo! Voices - November 27th, 2024
- How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline - November 27th, 2024
- RNA editing is the next frontier in gene therapy heres what you need to know - The Conversation - November 27th, 2024
- Assessment of gene therapy viral vectors in RPE cells - News-Medical.Net - November 27th, 2024
- Retinal organoids and RPE models for retinal gene therapy development - News-Medical.Net - November 27th, 2024
- China Vows to Bolster Gene Therapy Research in Key Biotech Hub - Bloomberg - November 27th, 2024
- Gene Therapy - Volume 31 Issue 11-12, November 2024 - Nature.com - November 27th, 2024
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire - November 27th, 2024
- Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News - November 27th, 2024
- New CRISPR system pauses genes, rather than turning them off permanently - Livescience.com - November 27th, 2024
- Liver-targeting gene therapy lowers mice whole-body SMA symptoms - SMA News Today - November 27th, 2024
- Bright breakthroughs: Real stories of beating rare disease - Science - November 27th, 2024
- Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA... - November 27th, 2024
- A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network - November 3rd, 2024
- Hemophilia B: Gene Therapy Shows Promise - Medscape - November 3rd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 30, 2024 - CGTLive - November 3rd, 2024
- 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice - November 3rd, 2024
- Cell therapy weekly: support for commercialization of complex therapies - RegMedNet - November 3rd, 2024
- Lexeo shares early data on Alzheimers gene therapy - Endpoints News - November 3rd, 2024
- Medicaid Aiming to Improve Patient Access to High-Cost Therapies - AJMC.com Managed Markets Network - November 3rd, 2024
- The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live - November 3rd, 2024
- OHSU researchers identify gene that could be key to future HIV vaccine - OHSU News - November 3rd, 2024
- Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech - November 3rd, 2024
- Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA... - November 3rd, 2024
- NewBiologix Launches Xcell to Accelerate, Optimize, and Scale Gene and Cell Therapy Production - Business Wire - November 3rd, 2024
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 - TIME - November 3rd, 2024
- Addressing gene and cell therapy commercialization challenges - TechTarget - November 3rd, 2024
- University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals - November 3rd, 2024
- Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter - November 3rd, 2024
- Behind the Breakthroughs: How to Turn $1,000,000 CAR Ts into Real Medicines - Inside Precision Medicine - November 3rd, 2024
- Terumo automates manufacturing to expand cell & gene therapies - European Pharmaceutical Manufacturer - November 3rd, 2024
- 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech - November 3rd, 2024
- Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire - November 3rd, 2024
- New FDA designations granted to NCATS for rare disease therapies. - NCBI - October 22nd, 2024
- $1.8 Million Awarded to Study the Durability of Gene Therapy - University of Arkansas Newswire - October 22nd, 2024
- By the numbers: US leads charge of cell and gene therapies - BioWorld Online - October 22nd, 2024
- University of Arkansas Researcher Awarded $1.8M for Gene Therapy Study - Arkansas Business - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - StockTitan - October 22nd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 16, 2024 - CGTLive - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- A New Type of Gene Therapy Shows Promise for Treating Retinitis Pigmentosa - Managed Healthcare Executive - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International - October 22nd, 2024
- When a Miracle Cure Is Left on the Shelf - Bloomberg - October 22nd, 2024
- Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire - October 22nd, 2024
- MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech - October 22nd, 2024
- 5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace - October 22nd, 2024
- Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz - October 22nd, 2024
- JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -... - October 22nd, 2024
- Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine - October 22nd, 2024
- The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times - October 22nd, 2024
- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of - PharmiWeb.com - October 22nd, 2024
- Gene therapy: advances, challenges and perspectives - PMC - October 6th, 2024
- Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace - October 6th, 2024
- Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow - FiercePharma - October 6th, 2024
- Meet Boston's National STEM Champion who's a junior in high school studying gene therapy - CBS Boston - October 6th, 2024
- Gene therapy research offers hope for kids with life-altering condition - WCVB Boston - October 6th, 2024
- Is gene therapy the next big step in vision loss treatment? - Medical News Today - October 6th, 2024
- Protein's Role in Insulin Signaling Could Have Implications for Gene Therapy - AJMC.com Managed Markets Network - October 6th, 2024
- Scientists overcome major challenge in gene therapy and drug delivery - News-Medical.Net - October 6th, 2024
- Innovative gene therapy for hemophilia - healthcare-in-europe.com - October 6th, 2024
- The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites - PR Newswire - October 6th, 2024
- Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now - Quartz - October 6th, 2024
- Cell therapy weekly: Promising Phase I results for Parkinsons disease cell therapy - RegMedNet - October 6th, 2024
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC - Nature.com - October 6th, 2024
- Forge Biologics Announces the FUEL AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production -... - October 6th, 2024
- Ninth Circuit Decision Marks Critical Legal Victory for U.S. FDA in Mission to Protect Patients from Unregulated Cell Therapy Products - PR Newswire - October 6th, 2024
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024